Optiwise
Optiwise, licence 80139013: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- LutAura PE
- Licence holder
- Altheda Wellness Innovation Inc.
- NPN or DIN-HM
- 80139013
- Status
- Active licence
- Licence date
- 7 March 2025
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| N-(2-Hydroxyéthyl)hexadécanamide Source : Palmitoyléthanolamide | 300.0 mg | Not calculated |
| Lutéine Source : Tagetes erecta - Oléorésine (herbe en fleurs) | 5.0 mg | Not calculated |
Non-medicinal ingredients
Hypromellose, Gomme arabique, Carraghénine, Lécithine, Curcuma, Cellulose microcristalline, Dioxyde de silicium, Eau, Acétate de potassium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 18.0 Année(s) | 1.0 Capsule | 2.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps to improve macular pigment optical density. Helps to maintain eyesight/support eye health in conditions (associated with sunlight damage), such as cataracts and age-related macular degeneration. Helps to reduce the risk of developing cataracts. Source of/Provides (an) antioxidant(s) (for the maintenance of good health). Source of/Provides (an) antioxidant(s) for the maintenance of eye health. Helps (to) reduce pain associated with inflammation. Helps relieve minor (chronic) (neuropathic) (joint) pain.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80139013
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.